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Foreword | Prisoners experience high 
rates of drug dependence, health 
problems and premature mortality. 
Without intervention, they often come 
into further contact with the criminal 
justice system, creating further health 
risk. Opioid dependence is common 
among prisoners, yet treatment with 
opioid substitution therapy (OST) may 
reduce or prevent morbidity, mortality 
and offending.
Using retrospective data linkage, this 
study evaluated engagement with 
treatment, patterns of offending, 
incarceration and mortality among 
opioid-dependent people who received 
OST in New South Wales, Australia 
between 1985 and 2010.
The results highlight that the prison 
setting provides an important 
opportunity to engage people in OST. 
Notably, OST treatment in prison and 
immediately post-release was found to 
be highly protective against mortality 
both while incarcerated and after 
release. Considering some of the 
known benefits of OST, this study 
provides strong evidence to support 
the value of OST programs within the 
criminal justice system.
Adam Tomison  
Director
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Prisoners are one of the most vulnerable groups in the community, experiencing high rates 
of mental illness, drug and alcohol dependence, chronic health conditions, exposure to 
violence, stigmatisation, social isolation and mortality (Kariminia et al. 2007). The World 
Health Organization (WHO 2010: np) states that
[p]risoners are members of the general population: they come from and usually return to 
the community. The relation between the health of prisoners, their families and the wider 
community is thus an acute concern.
Crime also carries costs to the wider community—impacts upon public amenity, financial 
loss, personal/property damage and the public health burden associated with premature 
morbidity and mortality of prisoners.
Prisoners have elevated rates of heroin dependence relative to the general population 
(Butler et al. 2004). Heroin dependence significantly impacts public health and public order, 
and has the greatest impact of all illicit drugs in Australia and globally (Begg et al. 2007; 
Degenhardt et al. 2013b).
Opioid dependence is commonly managed through the use of opioid substitution therapy 
(OST—methadone or buprenorphine maintenance), which is effective in achieving a number 
of positive treatment outcomes (Mattick et al. 2014)
Using a population of opioid-dependent people in New South Wales, Australia, the aims of 
the current study were to examine the:
• natural history of criminal justice system involvement among opioid dependent people, 
1993–2011;
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• extent of imprisonment of opioid 
dependent people, 2000–12;
• potential differences in the impacts 
of buprenorphine and methadone on 
treatment retention and mortality;
• differences in OST engagement and 
crime among Aboriginal and Torres Strait 
Islanders;
• gender differences in OST engagement;
• association between retention in OST 
and crime among opioid-dependent 
people;
• impact of OST provision in prison on in-
prison mortality;
• impact of OST on mortality following 
release from prison; and
• cost effectiveness of OST in reducing 
mortality post-release among this group.
Many of these results have already been 
published, or are currently in the process of 
being peer-reviewed for publication. For that 
reason, the key findings from each piece of 
work are summarised here and interested 




This study involved the linkage of four 
datasets:
• Pharmaceutical Drugs of Addiction 
System (PHDAS) at the NSW 
Department of Health.
• National Death Index (NDI) at the 
Australian Institute of Health and 
Welfare.
• Offender Integrated Management 
System at the NSW Department of 
Corrective Services.
• Reoffending Database (ROD) at the 
Bureau of Crime Statistics and Research 
(BOCSAR).
The Pharmaceutical Drugs of Addiction 
System
PHDAS is a database of all methadone 
and buprenorphine recipients in New 
South Wales, as notified to the NSW 
Pharmaceutical Services Branch since 
1985. Clients in the PHDAS are fully 
identified and the database records each 
client’s full name, date of birth, sex, treatment 
entry and exit dates, the type of OST 
medicine received, the approved prescriber, 
the treatment setting (community or prison) 
and the reason for exiting treatment.
National Death Index
The NDI is a database held by the Australian 
Institute of Health and Welfare and contains 
fully identified mortality data collected 
from each of the state and territory Births, 
Deaths and Marriage Registers. It collects 
information including date, state and causes 
of death (primary causes for all records, 
secondary causes for deaths occurring 
1997 and later).
Offender Integrated Management 
System
The Offender Integrated Management 
System is an administrative database 
of the NSW Department of Corrective 
Services. An extract from this system’s fully 
identified ‘Prisoner database’ was used to 
obtain demographic and criminographic 
information about all adults in full-time 
custody in New South Wales.
Reoffending Database
ROD was developed by BOCSAR to 
investigate reoffending. It is an identified, 
internally linked dataset of court records 
and contains records of all finalised court 
appearances in the Local, District and 
Supreme Courts of New South Wales 
since 1993.
Results
The natural history of criminal 
justice system involvement among 
opioid-dependent people, 1993–
2011
Studies of offending among people who use 
drugs typically focus on small and potentially 
unrepresentative samples. In this study, 
opioid-dependent NSW clients’ contact with 
the criminal justice system was examined 
to develop population-wide measures of 
offending among opioid-dependent people 
(Degenhardt et al. 2013a).
Data on all entrants to OST for opioid 
dependence between 1985 and 2010 
(n=48,069) were linked to data on court 
appearances from 1 December 1993 
to 31 March 2011. Person years (PY) of 
observation and charge rates for major 
crime categories estimated by sex, age and 
time were calculated.
A total of 638,545 charges were laid against 
cohort members during the follow-up period. 
Eight in 10 males (79.7%) and 67.9 percent 
of females had at least one charge; rates 
were 94.15 per 100 PY (95% CI 93.89–
94.41) among males and 53.19 per 100 
PY (95% CI 52.91–53.46) among females, 
and highest at 15–19 years (175.74 per 100 
PY males (95% CI 174.45–177.03), 75.60 
per 100 PY females (95% CI 74.46-76.76)) 
and 20–24 years (144.61 per 100 PY males 
(95% CI 143.70–145.53), 84.50 per 100 PY 
females (95% CI 83.53–85.48)).
The most frequent charges were theft 
(24.5% of all charges), traffic/vehicle 
offences (16.3%), offences against justice 
procedures (10.5%), illicit drug offences 
(10.0%), intentional injury offences (9.9%) 
and public order offences (8.9%).
Overall, 20.8 percent of the cohort 
accounted for 67.4 percent of charges. The 
top most frequently appearing 5.6 percent 
of the cohort accounted for 24.3 percent of 
costs ($75.5m). Among opioid-dependent 
people in Australia, a minority account for 
the majority of the criminal justice contact 
and levels of offending are not consistent 
over time, sex or age.
The extent of imprisonment of 
opioid-dependent people, 2000–12
There are few data about the incarceration 
of opioid-dependent people involving 
large representative cohorts. This study 
aimed to determine the prevalence and 
duration of incarceration in a large cohort 
of opioid-dependent people and estimate 
the costs associated with their incarceration 
(Degenhardt et al. 2014a).
All entrants to OST in New South Wales, 
1985–2010 were linked to incarceration 
records, 2000–12 (n=47,196). The 
number and duration of incarcerations 
were calculated. The average daily cost 
of incarceration was applied to days of 
incarceration in the cohort to examine the 
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costs associated with incarceration of this 
cohort across the observation period.
Almost four in 10 of the cohort (37%; 
43% of men and 24% of women) had at 
least one episode of incarceration. Men 
had a median of three (ranging between 
1–47) incarcerations and women had 
two (ranging between 1–35). Indigenous 
men spent 23 percent of their follow-up 
time incarcerated, compared with eight 
percent for non-Indigenous men. Similarly, 
Indigenous women spent a substantially 
greater proportion of time incarcerated than 
non-Indigenous women (8% vs 2%).
Costs of incarceration of this cohort 
between 2000 and 2012 totalled nearly 
A$3b. These findings suggest that a 
substantial minority of opioid-dependent 
people experience incarceration, usually on 
multiple occasions and at significant cost.
Potential differences in the impacts 
of buprenorphine and methadone 
on treatment retention and 
mortality
Research suggests methadone and 
buprenorphine may be differentially 
suited to particular groups of people and 
particular settings (Mattick et al. 2014). 
The aims of this study were to compare 
the characteristics of first-time methadone 
and buprenorphine treatment entrants, 
track treatment discontinuation and re-
entry with methadone and buprenorphine, 
and examine the factors associated with 
an individual’s risk of leaving their first OST 
treatment episode (Burns et al. 2014).
Records for all OST entrants in New South 
Wales between August 2001 and December 
2010 (N=32,033) were linked to records of 
custody episodes (2000–12). 
There were 15,600 first time OST 
entrants—7,183 (46%) commenced 
buprenorphine and 8,417 (54%) 
methadone. Fifty-six percent of those who 
commenced buprenorphine spent fewer 
than three months in treatment, compared 
with 30 percent who commenced 
methadone. Retention in treatment at 
12 months was higher among those 
commencing methadone (44%) compared 
with buprenorphine (25%). However, 12 
month buprenorphine retention increased 
by 10 percent from 2001–10, whereas 
methadone retention decreased by 
three percent. Multivariable Cox models 
indicated that in addition to sex, age, 
treatment setting and criminographic 
variables, risk of leaving a first treatment 
episode was greater on any given day for 
those receiving buprenorphine and was 
dependent on the year treatment was 
initiated.
It was concluded that individuals commencing 
methadone are retained longer in treatment 
than those commencing on buprenorphine, 
although buprenorphine retention has 
improved over time.
Differences in engagement with 
opioid substitution therapy and 
crime among Aboriginal and Torres 
Strait Islanders
Although Indigenous Australians are 
overrepresented among heroin users, no 
study has examined offending, time in 
custody and OST treatment utilisation among 
Indigenous opioid-dependent people at the 
population level, nor compared these with 
non-Indigenous opioid-dependent people. 
The aims of this study were to compare the 
nature and types of offences, time in custody 
and OST treatment utilisation between 
opioid-dependent Indigenous and non-
Indigenous Australians in contact with the 
criminal justice system (Gisev et al. 2014b).
Using linked records of OST entrants in 
New South Wales (1985–2010), court 
appearances (1993–2011) and custody 
episodes (2000–12), rates of criminal charges 
per 100 person–years were compared 
between Indigenous and non-Indigenous 
Australians. Comparisons were also made 
between Indigenous and non-Indigenous 
Australians for time spent in custody, as well 
as characteristics of OST utilisation.
Of the 34,962 people in the cohort, 6,830 
were Indigenous and 28,132 were non-
Indigenous. Among the 6,830 Indigenous 
people, 4,615 (67.6%) were male and 2,215 
(32.4%) female. The median number of 
charges against Indigenous people (25, IQR 
31) was significantly greater than for non-
Indigenous people (9, IQR 16) (p<0.001). 
Overall, Indigenous people were charged 
with 33.2 percent of the total number 
of offences against the cohort and 44.0 
percent of all violent offences. The median 
proportion of follow-up time that Indigenous 
males and females spent in custody was 
twice that of non-Indigenous males (21.6% 
vs 10.1%; p<0.001) and females (6.1% 
vs 2.9%; p<0.001). The proportion of 
Indigenous people who first commenced 
OST in prison (30.2%) was three times 
that of non-Indigenous people (11.2%; 
p<0.001). Indigenous males spent less 
time in OST compared with non-Indigenous 
males (median proportion of follow-up time 
in treatment: 40.5% vs 43.1%; p<0.001).
Indigenous opioid-dependent people in 
contact with the criminal justice system 
are therefore charged with a greater 
number of offences, spend longer in 
custody and commonly initiate OST in 
prison. Criminal justice system contact 
is an important opportunity to engage 
Indigenous people in OST.
Gender differences in opioid 
substitution therapy engagement
Few population-based studies have 
examined differences in OST treatment 
utilisation between men and women. This 
study compared first episode and long-term 
OST treatment utilisation profiles between 
men and women, differentiating between 
treatment initiation in the community and in 
custody (Gisev et al. 2014a).
Records of new OST entrants (2001–10) were 
linked to custody episodes (2000–12). First 
OST treatment episode and overall treatment 
utilisation characteristics were compared 
between men and women initiating treatment 
in the community or in custody. Treatment 
retention was evaluated at three, six, nine and 
12 months after first commencing OST and 
overall as the median proportion of follow-up 
time spent in treatment.
There were 15,600 first-time OST entrants in 
the cohort during the follow-up period. This 
included 10,930 men (70.1%) and 4,670 
women (29.9%). A substantial minority 
initiated treatment in custody (n=3,016, 
19.3%). More men than women began OST 
in custody (24.0% vs 8.3%; p<0.001) and 
only ever received OST in custody (57.5% 
vs 41.8%; p<0.001). Women were retained 
longer in their first OST treatment episode 
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at three, six, nine and 12 months post-entry 
into treatment. They also spent more of 
their overall follow-up time in treatment. The 
median proportion of follow-up time spent 
in treatment was higher among women 
than men initiating treatment in both the 
community (46.6% (IQR 74.9) vs 39.1% 
(IQR 72.4)) and custody (41.3% (IQR 61.4) 
vs 30.8% (IQR 55.1)).
It was concluded that there are a number of 
key differences in OST treatment utilisation 
profiles between men and women. Whereas 
men commonly initiate and only receive OST 
in custody, treatment retention is higher 
among women, independent of the setting 
treatment is initiated.
The association between retention 
in opioid substitution therapy and 
crime among opioid-dependent 
people
Following on from the study of patterns of 
offending among opioid-dependent people, 
the effect of OST treatment and retention 
on crime rates among 10,744 opioid-
dependent people who first entered OST on 
or after 1 January 2004 was also examined. 
This allowed a comparison of crime rates in 
the four years immediately prior to treatment 
entry (the average time before an individual 
enters treatment after becoming opioid 
dependent), as well as periods in and out of 
OST after initiating treatment. Time spent in 
custody over this period was adjusted for.
The crude crime rate (CCR) per 100 PY for 
the total number of offences that individuals 
were charged with prior to treatment entry 
was 130.78 (95% CI 129.65–131.91). A 32 
percent reduction was observed in the CCR 
while individuals were in OST (CCR 88.29, 
95% CI 86.96–89.63) and a 20 percent 
reduction was observed while individuals 
were out of OST (CCR 101.67, 95% CI 
100.35–102.99). When comparing the crime 
rates after treatment entry only, a 15 percent 
increase in the CCR was observed over the 
period individuals were not receiving OST.
The effect of treatment retention on crime 
rates was evaluated for individuals who 
were in OST for at least three months 
(n=7,546), six months (n=6,685), nine 
months (n=6,072) and 12 months 
(n=5,586). There was a clear reduction in 
the total CCR the longer individuals were in 
treatment—85.72 (95% CI 84.40–87.05) at 
three months, 82.78 (95% CI 81.48–84.10) 
at six months, 79.20 (95% CI 77.91–80.50) 
at nine months and 76.50 (95% CI 75.22–
77.80) at 12 months.
Overall, entry into OST had a positive effect 
on reducing crime rates among people with 
established opioid dependence. Lower 
crime rates were observed during periods 
in OST and greatest reductions were 
observed among people who were retained 
longer in treatment.
The impact of opioid substitution 
therapy provision in prison upon 
in-prison mortality
Deaths in prison are a significant concern 
and correctional authorities have a 
responsibility to ensure that such deaths 
are kept to a minimum. Opioid-dependent 
people commonly experience imprisonment 
(as documented earlier in this cohort) and 
may be at particular risk of death in prison. 
OST reduces mortality among opioid-
dependent people residing in the community, 
but it is unclear if this is also the case in 
prison. This study aimed to describe deaths 
in prison among opioid-dependent people 
and examine associations between receipt 
of OST and risk of death in prison (Larney et 
al. 2014).
The cohort in this analysis included all 
opioid-dependent people who entered 
prison at least once (n=16,715) in New 
South Wales between 2000 and 2012. 
Rates of mortality during different periods in 
prison were examined, as were both natural 
and unnatural (suicide, drug-induced, violent 
and other injury) deaths in prison.
Cohort members were in prison for 30,998 
PY, during which time there were 51 deaths. 
The all-cause crude mortality rate (CMR) in 
prison was 1.6 per 1,000 PY (95% CI: 1.2, 
2.2 per 1,000 PY) and the unnatural death 
CMR was 1.1 per 1,000 PY (95% CI: 0.8, 
1.6 per 1,000 PY).
Compared with time out of OST, the 
hazard of all-cause death was 74 percent 
lower while in OST (adjusted hazard ratio; 
AHR): 0.26; 95% CI: 0.13 to 0.50) and the 
hazard of unnatural death was 87 percent 
lower while in OST (AHR: 0.13; 95% CI: 
0.05 to 0.35). The all-cause and unnatural 
death CMRs during the first four weeks of 
incarceration were 6.6 per 1,000 PY (95% 
CI: 3.8, 10.6 per 1,000 PY) and 5.5 per 
1,000 PY (95% CI: 2.9, 9.4 per 1,000 PY), 
respectively. Compared with periods not in 
OST, the hazard of all-cause death during 
the first four weeks of incarceration was 
94 percent lower while in OST (AHR: 0.06; 
95% CI: 0.01 to 0.48) and the hazard of 
unnatural death was 93 percent lower while 
in OST (AHR: 0.07; 95% CI: 0.01 to 0.53).
Mortality of opioid-dependent prisoners was 
significantly lower while in receipt of OST. In 
addition to other known benefits of OST in 
prison (eg reduced opioid use and injecting 
drug use), to-scale provision of OST in 
prisons will dramatically reduce unnatural 
deaths among opioid-dependent prisoners.
The impact of opioid substitution 
therapy on mortality following 
release from prison
The immediate period post-release from 
prison carries a high risk of mortality for 
ex-prisoners, particularly among those 
who use (and return to) drugs (Merrall et al. 
2010). There has been little evaluation of 
interventions to reduce this mortality risk. 
No study to date has reported the impact 
of OST treatment provided during and after 
incarceration on mortality in the high-risk 
first month post-release (Degenhardt et al. 
2014b).
A cohort was formed of all opioid-
dependent people who entered OST in 
New South Wales between 1985–2010 
and who following OST entry were released 
from prison at least once between 2000–12 
(n=16,453 individuals, who were released 
60,161 times across this period). Data on 
OST history, court and prison records, and 
deaths were linked. CMRs were calculated 
according to OST retention; multivariable 
Cox regressions for post-release periods 
were undertaken to examine the association 
between OST exposure (a time dependent 
variable) and mortality post-release, for 
which covariates were updated per-release.
There were 100,978 PY of follow-up post-
release, during which time 1,050 deaths 
occurred for a CMR of 10.4 per 1,000 
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PY (95% CI: 9.8–11.0). Accidental drug-
induced deaths were the most common 
cause of death.
Most individuals had received OST at 
some point while incarcerated (76.5%) and 
individuals were receiving OST in around 
half (51%) of prison releases. Lowest 
post-release mortality was among those 
continuously retained in OST post-release 
(CMR 4 weeks post-release: 6.4 per 1,000 
PY; 95% CI: 5.2, 7.8) and highest among 
those with no OST (CMR: 36.7 per 1,000 
PY; 95% CI: 28.8, 45.9).
Multivariable Cox regression models 
showed that OST exposure in the four 
weeks post-release reduced the hazard of 
death by 75 percent (adjusted hazard ratio 
0.25; 95%CI: 0.15, 0.52); OST receipt in 
prison had a short-term protective effect 
that decayed quickly across time.
This study provides persuasive evidence 
that OST provision in prison and post-
release reduces mortality risk in the 
immediate post-release period. It was 
concluded that OST in prison and post-
release reduces mortality risk in the 
immediate post-release period. OST in 
prison should be scaled up and post-
release OST continuation maximised.
Cost effectiveness of opioid 
substitution therapy in reducing 
mortality post-release among this 
group
Based on the previous cohort, this study 
aimed to undertake a cost-effectiveness 
analysis of the immediate uptake of OST 
post-release from prison relative to not 
receiving OST immediately upon release in 
saving lives in the first six months post-
release (Gisev et al. forthcoming).
To allow for each person to have six months 
of follow-up, the cost-effectiveness analysis 
focused on those 16,073 people who were 
released on or before 30 June 2011.
Using information from each individual’s 
first recorded prison release after 
commencing treatment, two groups 
of people were identified—those who 
were released onto OST (n=7,892) and 
those who were not released onto OST 
(n=8,181). Mortality was evaluated at six 
months after the first prison release.
Costs and resources included were all OST 
received by both groups in the six months 
follow-up (as measured in AUD2012), 
costs to the criminal justice system (proven 
charges processed by the court, police, 
penalties, prison) as well as the social costs 
of crime from the first day post-release to 
death, or 180 days post-release (whichever 
occurred first).
The crude average costs incurred per 
person for the first six months post release 
were estimated for the two groups. These 
were $14,962 per person for those released 
onto OST and $11,878 for those not 
released onto OST. In total across the six 
month period, there were 35 fewer deaths 
observed among those released onto OST. 
This equates to a cost of about $88.14 per 
death prevented.
Discussion
This study has elucidated the patterns of 
offending, engagement with treatment and 
incarceration of opioid-dependent people 
in New South Wales across more than two 
decades.
Most cohort members (75.8%) had appeared 
before court for criminal charges, with men 
more likely to do so and on a larger number 
of occasions than women.
During 2000–12, over one-third of the cohort 
was incarcerated at least once, often on more 
than one occasion, and the costs associated 
with this are considerable. In any given year, 
around one in seven was incarcerated, with 
some variation across calendar years in 
these levels. The cumulative incidence of 
incarceration in the cohort is lower than has 
previously been reported in studies using 
smaller or convenience samples of opioid 
users or people who inject drugs (Kirby 
Institute 2012; Phillips & Burns 2012). The 
findings clearly suggest that care should be 
taken in extrapolating incarceration prevalence 
from selected samples of opioid users, given 
the lower levels determined in this cohort.
Through the use of a population-wide 
linkage, the limitations of small, selective, 
and possibly unrepresentative samples, 
were able to be avoided. Although it is 
possible that opioid-dependent people who 
seek treatment differ from those who do 
not, the representativeness of this cohort 
is likely to be high as studies in New South 
Wales consistently find that the majority of 
heroin users have received OST at some 
point in their lives (Kirby Institute 2012; 
Phillips & Burns 2012).
This large-scale linked data study has also 
demonstrated the high mortality risk that 
opioid-dependent prisoners face after 
prison release, particularly from accidental 
drug-induced deaths, suicide, accidental 
injury and violence. This is not unexpected 
considering that upon release, these people 
often experience poor social support, 
isolation, medical comorbidities, financial 
stress, debts and continued exposure to 
drugs in the communities to which they 
return (Binswanger et al. 2012).
This study provides unequivocal evidence of 
the significant benefit of OST on post-release 
mortality of opioid dependent people leaving 
prison. Post-release OST exposure was 
highly effective in reducing the mortality risk in 
the first month at liberty. The lowest mortality 
rates were seen in those persons who were 
continuously retained in OST after release, 
whereas the highest mortality rates were 
seen in those opioid dependent persons with 
no OST in the post-release period.
OST provision in prison and post-release 
independently reduce mortality in the 
immediate post-release period. Prison OST 
is also effective in reducing drug-related 
HIV risk behaviours (Larney 2010), and 
significantly increases the probability that 
someone will enter OST in the days after 
release (Kinlock et al. 2007); there are also 
impacts of prison-based and post-release 
OST on risk of reincarceration (Larney et al. 
2012). Despite these benefits, considerable 
inequities remain in the provision of care 
for opioid-dependent people in prisons 
compared with those in the community 
(Harm Reduction International 2012; Nunn 
et al. 2009). Although international agencies 
have emphasised its effectiveness (Jürgens, 
Ball & Verster 2009; Stallwitz & Stover 
2007), policymakers in many countries 
are resistant to calls for OST in prison 
settings (McKenzie et al. 2009). In light of 
the increasingly robust scientific evidence 
demonstrating the benefits of prison OST, 
continued resistance to implementing and 
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expanding OST in correctional settings 
seems unwarranted.
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